Carlos Ibañez, PhDFounder, Chief Technology Officer at Abintus Bio Inc.
Carlos E. Ibañez is a cofounder of Abintus Bio Inc. and serves as Chief Technology Officer. Abintus is a preclinical-stage genetic medicines company pioneering the reprogramming of cells directly inside the patient. Dr. Ibañez brings 29+ years of experience combining process engineering and cell biology for the development of novel gene and cell therapies agents from start-up through Phase III PPQ validation for companies such as Viagene Inc, Chiron Corporation, BioMedica Inc., NovaRx and Tocagen Inc. His interests include: (1) Strategies for achieving a product pipeline from a standardized modular viral delivery platform; (2) development of stable and high-titer viral vector producing cell lines; (3) continuous perfusion-based, single-use bioreactor systems; (4) scalable viral vector purification strategies; (5) biological formulations for direct intravenous delivery; and (6) effective analytical testing strategies for lot release, stability, product characterization and comparability. Dr. Ibañez received his Ph.D. in Molecular Pathology from the UC, San Diego, and was a Post-Doctoral fellow at the Research Institute at Scripps Clinic focusing on viral and host cellular interactions.